^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
58 Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
Published date:
11/03/2022
Excerpt:
To perform a retrospective analysis of outcomes of 7+3 plus GO vs 7+3 in ND intermediate-risk cytogenetic AML pts treated at a single comprehensive cancer center....Non-responders to 7+3 plus GO were enriched for ASXL1, DNMT3A, TET2, and TP53 mutations as compared to responders who harbored more FLT3, IDH1/2, KRAS/NRAS and RUNX1 mutations.
Secondary therapy:
cytarabine + daunorubicin
DOI:
https://doi.org/10.1182/blood-2022-168482
